Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Understanding Brain Diseases: From Receptor Dysregulation to Neurodegeneration, Neuroinflammation and Memory Impairment

Author(s): Fabiola M. Ribeiro

Volume 21, Issue 2, 2023

Published on: 12 December, 2022

Page: [162 - 163] Pages: 2

DOI: 10.2174/1570159X2102221212143233

Price: $65

« Previous Next »
[1]
Mortberg, M.A.; Vallabh, S.M.; Minikel, E.V. Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. Sci. Rep., 2022, 12, 17708.
[2]
Gilhus, N.E.; Deuschl, G. Neuroinflammation - a common thread in neurological disorders. Nat. Rev. Neurol., 2019, 15, 429-430.
[3]
Schirinzi, T.; Canevelli, M.; Suppa, A.; Bologna, M.; Marsili, L. The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal. Rev. Neurosci., 2020, 31, 723-742.
[4]
Correa, B.H.M.; Moreira, C.R.; Hildebrand, M.E.; Vieira, L.B. The role of voltage gated calcium channels in basal ganglia neurodegenerative disorders. Curr. Neuropharmacol., 2023, 21(2), 183-201.
[5]
de Lima, I.B.Q.; Ribeiro, F.M. The implication of glial metabotropic glutamate receptors in Alzheimer’s disease. Curr. Neuropharmacol., 2023, 21(2), 164-182.
[6]
Abd-Elrahman, K.S.; Sarasija, S.; Ferguson, S.S.G. The role of neuroglial metabotropic glutamate receptors in Alzheimer’s disease. Curr. Neuropharmacol., 2023, 21(2), 273-283.
[7]
Martins, G.L.; Ferreira, C.N.; Palotas, A.; Rocha, N.P.; Reis, H.J. Role of oxysterols in the activation of the NLRP3 inflammasome as a potential pharmacological approach in Alzheimer’s. Curr. Neuropharmacol., 2023, 21(2), 202-218.
[8]
Koerich, S.; Parreira, G.M.; de Almeida, D.L.; Vieira, R.P.; de Oliveira, A.C.P. Receptors for advanced glycation end products (RAGE): Promising targets aiming at the treatment of neurodegenerative conditions. Curr. Neuropharmacol., 2023, 21(2), 219-234.
[9]
Martins, L.B.; Silveira, A.L.M.; Teixeira, A.L. The involvement of kynurenine pathway in neurodegenerative diseases. Curr. Neuropharmacol., 2023, 21(2), 260-272.
[10]
Yang, M.; Wang, C.; Zhao, G.; Di, K.; Liju, L.; Shuai, Y.; Wei, C.; Can, F.; Zezhi, L. Comparative analysis of the pre- and post-medicative effects of antipsychotic agents on the blood-based oxidative stress biomarkers in patients with schizophrenia: a meta-analysis. Curr. Neuropharmacol., 2023, 21(2), 340-352.
[11]
Asth, L.; Cruz, L.C.; Soyombo, N.; Rigo, P.; Moreira, F.A. Effects of beta-caryophyllene, a dietary cannabinoid, in animal models of drug addiction. Curr. Neuropharmacol., 2023, 21(2), 213-218.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy